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Abstract 
Vascular complications are an important pathological issue in diabetes, which lead to further 
functional deterioration of several organs. The balance between endothelium-dependent 
relaxing (EDRF) and endothelium-dependent contracting (EDCF) factors is crucial in 
controlling local vascular tone and function under normal conditions.  Diabetic endothelial 
dysfunction is characterized by reduced endothelium-dependent relaxations and/or enhanced 
endothelium-dependent contractions. Elevated levels of oxygen-derived free radicals are the 
initial source of endothelial dysfunction in diabetes. Oxygen-derived free radicals not only 
reduce nitric oxide bioavailability, but also facilitate the production and/or the action of 
EDCFs. Thus, the endothelial balance tips towards vasoconstrictor responses in the course of 
diabetes.  
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Diabetes mellitus groups heterogeneous etiologies, but shares abnormalities in carbohydrate, 
fat and protein metabolisms. Long-term diabetes affects many organ systems. The vascular 
consequences of the disease can be subdivided into microvascular (retinopathy and 
nephropathy) and macrovascular complications (coronary and peripheral arterial disease). 
Whereas the former lesions are relatively unique for diabetes, the latter are similar both 
morphologically and functionally with atherosclerotic lesions due to other causes. Since 
diabetes is such an important risk factor for the occurrence of atherosclerosis and coronary 
heart disease, not surprisingly cardiovascular disease is the leading cause of morbidity and 
mortality in diabetic patients 1.  
A large body of evidence demonstrates the impairment of endothelium-dependent 
vasodilatation in cardiovascular diseases such as hypertension, hypercholesterolemia, 
atherosclerosis, and heart failure 2-5. However the available data are not so conclusive as 
regards to diabetes 6. Thus, the present non-exhaustive review will focus on the impact of 
diabetes on vascular dysfunction, in particular on endothelium-derived vasoactive factors.  
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Endothelial Dysfunction in Diabetes 
Endothelium-derived Nitric oxide is essential for the local control of vascular diameter 7-9.  
In type I diabetic animals,  acetylcholine-induced relaxations are potentiated in the rat aorta 
and canine coronary arteries 10-12, normal in the aorta 13-16 and the mesenteric arteries 14 of the 
rat, and/or depending on the authors, blunted in the same blood vessels17-18. Moreover, NO-
mediated relaxation is augmented at the early stage of diabetes followed by an impaired 
relaxation as the disease progresses 19-20. Likewise, in type I diabetes patients, endothelium-
dependent relaxations are impaired 4, 21-23, normal 24-28 or enhanced 29.  
In type II diabetic animals, NO-mediated relaxation is increased 30, preserved 31 or reduced 32 
in the aorta of obese Zucker fatty rats. Blunted NO-mediated relaxations are observed in 
carotid and mesenteric arteries from Zucker rats 33-34, mesenteric arteries from db/db mice 35-36 
and coronary arteries of db/db mice 37-38. In type II diabetes patients, blunted dilatations are 
observed consistently 39-40. The evidence suggesting an impairment of endothelium-dependent 
vasodilatation in type II diabetes is more obvious than in type I diabetes, since the former is 
almost inevitably confounded by the high prevalence of other cardiovascular risk factors that 
are known to affect endothelial functions 41. Several studies demonstrated impaired 
endothelium-dependent vasodilatation in patients with type II diabetes, but even after rigorous 
patient selection, mild dyslipidaemia or hypertension were often present 42-43. Thus it remains 
unclear whether or not diabetes type II per se affects endothelial function. 
 
Prostacyclin (PGI2) is not only an endothelium-derived relaxing factor 44-46 but also is an 
important inhibitor of platelet aggregation 47.  
In type I diabetes, prostacyclin contributes to the enhanced acetylcholine-induced and 
endothelium-dependent relaxation in the coronary artery of dogs 10 and the aorta of the mouse 
48. In addition, the oral administration of prostacyclin analogues restores the blunted 
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relaxation to acetylcholine in the rat aorta 49. These results indicate that prostacyclin takes part 
in the preservation of endothelium-dependent relaxation in diabetes, especial in type I.   
 
Endothelium-derived hyperpolarizing factors (EDHF) represent the third endothelium-
dependent vasodilator pathway(s) 50.  
EDHF-mediated responses are observed in certain blood vessels in the presence of inhibitors 
of cyclooxygenases and NO synthases and are associated with hyperpolarization of the 
vascular smooth muscle cell 50-55. EDHFs play a more pronounced role in the smaller arteries 
56-57. They are also regarded as an important compensatory mechanism in the absence or 
blockade of the production of nitric oxide 58-62. However the correlation between diabetes and 
endothelium-dependent hyperpolarization remains unclear.  
In type I diabetes, the endothelium-dependent response to acetylcholine attributed to EDHF is 
depressed in isolated rings of mesenteric arteries from streptozotocin-treated rats and mice, 
while the nitric oxide component is preserved 63-66. Nonetheless in the mesenteric artery of the 
same rat model, an augmented contribution of EDHF compensates for the blunted nitric oxide 
response 18. 
In type II diabetes, EDHF-mediated relaxations are reduced in the mesenteric artery of Goto-
Kakizaki rats 67, Zucker obese rats 68, and Otsuka-Long-Evans-Tokushima Fatty (OLETF) 
rats 69 when the nitric oxide mediated responses are not affected. However, the EDHF 
component is augmented in genetic diabetic (db/db) mice when nitric oxide bioavailability is 
reduced 70.  
 
Endothelium-derived and cyclooxygenase-dependent contracting factor (EDCF) is a 
hallmark of endothelial dysfunction. The product of cyclooxygenase activates thromboxane-
prostanoid (TP-) receptors 71-75. The nature of endothelium-derived contracting factor depends 
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on the experimental model studied and the stimulating agents used. It can be endoperoxide 76-
77, thromboxane A2 78-79, prostaglandin E2 79, or prostacyclin 80-82. 
In type I diabetes, the EDCF-mediated response is potentiated in the aorta of rabbits 83, the 
aorta of mice 84 and the femoral artery of rats (Figure 1) 79. In the mesenteric artery from rats 
with alloxan-induced diabetes, an increased production of prostanoids, presumable 
prostaglandin F2α, reduces the arterial diameter 85.  
In the renal artery of a type II diabetes model, the OLETF rat, indomethacin restores the 
blunted relaxation to acetylcholine 86. Similar results were obtained in the aorta from db/db 
mice 87. An augmented EDCF-mediated contraction is observed in the mesenteric artery of 
OLETF rats 88-89.  
 
Endothelin (ET) is also a hallmark of endothelial dysfunction. The contribution of ET-1 is 
not obvious in the early stages of diseases, indicating that the production of endothelin 
reflects an advanced or even terminal pathology 90. 
An ET-1 antagonist, J-104132 normalizes the up-regulation of p22phox subunit of NAD(P)H 
oxidase in streptozotocin-treated rats 91. Moreover, the dual blockade of ETA and ETB 
receptors enhances the endothelium-dependent vasodilatation to acetylcholine in insulin-
resistant patients 92. These observations suggest that ET-1 may play a role in the endothelial 
dysfunction of diabetes. 
 7
Reactive Oxygen Specials in Diabetes 
Reactive oxygen specials (ROS) are generated during normal metabolic processes, but at 
supra physiological levels they cause DNA mutation, protein oxidation and lipid peroxidation. 
Elevated production of reactive oxygen species is implicated in atherosclerosis, hypertension, 
cancer, diabetes and premature aging 93.  
Oxygen-derived free radical species originate from molecular oxygen. Superoxide anions (O2-
), hydrogen peroxide (H2O2), hydroxyl radical (OH-) and peroxynitrite (ONOO-) fall into this 
group. The special feature of these agents is their high oxidative reactivity, creating a 
significant threat for redox-sensitive components. Superoxide anions are the primary oxygen-
derived free radicals. They have a short half-life and are intracellular-restrained molecules. 
Unlike superoxide anion, hydrogen peroxide diffuses freely within tissues since it is not 
charged. The metal catalyzed interaction between hydrogen peroxide and superoxide anion 
produces hydroxyl radical. Reactive oxygen species can either be generated exogenously or 
produced intracellularly from several different sources. Cytosolic enzyme systems 
contributing to oxidative stress include the family of NADPH oxidases 94, mitochondria 95. In 
addition, xanthine oxidase, cytochrome P450(s), cyclooxygenases and NO synthase are 
capable of producing reactive oxygen species 96. 
The burden of free radical production is largely counteracted by the antioxidant defense 
system that includes the enzymatic scavenger superoxide dismutase (SOD), catalase and 
glutathione peroxidase (GPx). Superoxide dismutase speeds up the conversion of superoxide 
anions to hydrogen peroxide, whereas catalase and glutathione peroxidase convert hydrogen 
peroxide to water. A variety of other non-enzymatic, low molecular mass molecules are 
important in scavenging reactive oxygen species. These include ascorbate, pyruvate, 
flavonoids, and carotenoids, and perhaps most importantly, glutathione, which is present in 
millimolar concentrations within cells (Figure 2). 
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Imbalance of the oxygen-derived free radicals and antioxidant defense 
Diabetes increases the level of reactive oxygen species 96-102. These radicals play a crucial role 
in the pathogenesis of diabetes-associated vascular complications 96, 103-105. However, neither 
the exact source of the free radicals initiating the cascade leading to cell dysfunction in 
diabetes nor their exact chemical nature is fully understood. Under hyperglycemic and 
diabetic conditions, glycation reactions produce intermediate compounds that also increase 
the levels of reactive oxygen species 6, 103, 106-111. Dicarbonyl compounds such as 
methyglyoxal and 3-deoxyglucosone, intermediate products of glycation, are typical examples. 
The serum concentrations of both methyglyoxal and 3-deoxyglucosone are increased in 
patients with diabetes mellitus 112.  
In diabetes, it is also reported that the augmented production of oxidative specials results from 
a reduced activity of superoxide dismutase (Figure 3) 34, 100, 113-116 and catalase (Figure 4) 100, 
117, from reduced total glutathione level 100, 118, from increased activity of glutathione 
peroxidase 119-120, and from up-regulation of NADPH oxidase 34, 38, 115, 121-122 and 
cyclooxygenase (Figure 5) 79, 88-89, 123.  
 
NO and ROS 
Obviously nitric oxide is not the sole answer to the endothelial dysfunction of diabetes. The 
obligatory role of endothelium-derived nitric oxide was first reported in 1980 7. It is generated 
through the oxidation of L-arginine to L-citrulline by NO synthase (NOS). In blood vessels, 
endothelial NO synthase (eNOS) is constitutively active in the endothelium but the activity of 
the enzyme can be augmented further by stimuli that increase the intracellular calcium 
concentration124. The impact of diabetes on the presence of nitric oxide synthase is 
controversial. It is reduced 34, 37, 88, 116, 125, normal 79, 123, 126-127, or enhanced 128-129. Since nitric 
oxide has a half-life of only a few seconds 130 and is rapidly inactivated by hemoglobin and 
superoxide 8, 130,  the concept of loss of nitric oxide bioavailability is more precise and 
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important131. The blunted nitric oxide mediated response can be restored by the L-arginine, 
the substitute of nitric oxide synthase 132-133 or BH4, an essential cofactor of nitric oxide 
synthase 20, 36. Treatment with antioxidants also prevents the blunted relaxation 36. 
Uncoupled eNOS is an important source of reactive oxygen species under pathological 
condition 134-135. The production of peroxynitrite, a strong cytotoxic oxidant which is formed 
by the combination of nitric oxide and superoxide anions, also contributes to endothelial 
dysfunction 129, 136. When prostacyclin synthase in isolated arteries is inactivated by 
peroxynitrition, prostacyclin-dependent vasodilatation is replaced by prostaglandin-dependent 
vasoconstriction 131.  
 
EDHF and ROS 
Since the correlation between diabetes and endothelium-dependent hyperpolarization is 
inconclusive yet, it is difficult to link EDHF and oxidative stress.  Interestingly, hydrogen 
peroxide is proposed to be an endothelium-derived hyperpolarizing factor in the mesenteric 
artery of type II diabetic mice 137-138, the mesenteric artery of humans 139 and the porcine 
coronary artery 140.  
 
EDCF and ROS 
Oxygen-derived free radicals play an important role in the occurrence of endothelium-
dependent contractions in the basilar artery of the dog and the aorta of the spontaneously 
hypertensive rat 74, 81, 141-144. ROS potentiates endothelium-derived contracting factor in the 
aorta of the spontaneously hypertensive rats 144 and the femoral artery of streptozotocin-
induced type I diabetic rats (unpublished observation). The potentiating effect was not 
observed in the artery from control rats, suggesting that the redox abnormality is seen only 
under certain disease conditions.  
Oxygen-derive free radicals are also directly involved in the occurrence of the endothelium-
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derived contractions, since an increased oxidative state, measured by DCF fluorescence 
intensity using confocal microscopy, accompanies the genesis of endothelium-dependent 
contractions to acetylcholine or the calcium ionophore A23187 81, 100. Furthermore, tiron (an 
intracellular scavenger of superoxide anion) reduces endothelium-dependent contractions in 
the aorta of the spontaneously hypertensive rat 144 and the femoral artery of rats with 
streptozotocin-induced diabetes (Figure 6a) 100, indicating that superoxide anions inside 
endothelial cells are a primary oxidative contributor to endothelium-dependent contractions 72, 
100, 144. Catalase and deferoxamine reduce the endothelium-dependent contraction in the aorta 
of hypertensive rats 144 and in the femoral artery of diabetic rats (Figure 6b) 100, suggesting 
that hydrogen peroxide could be, at least the precursor of endothelium-derived contracting 
factor.  
In addition, hydroxyl radicals per se have been proposed as candidates for endothelium-
derived contacting factors. In the femoral artery of streptozotocin-induced type I diabetes, 
hydrogen peroxide produces moderate contractions in rings without endothelium which are 
prevented by catalase and deferoxamine, indicating that the contraction generated by 
exogenous H2O2 is presumably due to hydroxyl radicals, rather than hydrogen peroxide itself. 
The hydroxyl radicals-mediated contraction is comparable in amplitude to the deferoxamine-
sensitive part of the endothelium-dependent contraction in the same artery 100. A similar 
conclusion has been reached in the aorta of spontaneously hypertensive rats 144. 
 
Antioxidant treatment  
It seems reasonable to hypothesize that antioxidant treatment would prevent endothelial 
dysfunction in diabetes. In diabetic animals, vitamin E alone or combined with insulin 
prevents endothelial dysfunction 97, 145. Exercise which is assumed to reduce oxidative stress 
in vivo improves endothelial dysfunction 116. Folic acid restores the impaired endothelial 
function as well 41. Likewise, in diabetes patients, vitamin E, vitamin C, or folic acid improve 
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endothelial dysfunction 147-151. However, trials with these beneficial results are carried out in 
small-groups of patients whereas in large, long-term clinical trials, neither vitamin E nor 
vitamin C reduces the risk of cardiovascular events 152-154. Therefore, caution is required 
before drawing a conclusion as to the effectiveness of antioxidant treatments in vivo for the 
prevention of endothelial dysfunction in diabetes. 
 
Conclusion 
The endothelial dysfunction of diabetes includes reduced nitric oxide bioavailability and/or 
enhanced endothelium-dependent contractions which can be largely attributed to increased 
oxidative stress (Figure 7). Since the results of antioxidants in large clinic trials are not 
consistent with those in experimental animals, further investigation is critical to assess the 
exact role of ROS on the genesis of endothelial dysfunction, in particular in diabetes. 
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Legends 
Figure 1. Contractions to A23187 in femoral arteries from control and streptozotocin-treated 
rats in the presence of L-NAME (0.3 mM) after 4 (a and b) and 12 (c and d) weeks. Data 
shown are means±SEM, (vertical lines); n=7. *Significant difference from control rings 
(P<0.05). #Significant difference from rings of control rats under identical conditions 
(P<0.05). L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride. (From Shi et al., 2007, 
with permission 79) 
Figure 2. The generation of reactive oxygen species. ROS: reactive oxygen species; GSH: 
glutathione; GSSG: glutathione disulfide; NAD(P)H: nicotinamide adenine dinucleotide 
phosphate-oxidase; NO: nitric oxide (Modified from Shi et al., 2007, with permission 100). 
Figure 3. Presence of Mn-SOD (a, b) and copper–zinc-SOD (c, d) in femoral arteries with 
endothelium from control and STZ-treated rats. Representative western blots demonstrating 
the presence of proteins (a and c) and graphic representation of the data (b and d), normalized 
to β-actin, presented as percentage of control and shown as means±SEM, n=6. *Significant 
difference from controls (P<0.05). STZ, streptozotocin. CuZn-SOD, copper–zinc-SOD; Mn-
SOD, manganese-superoxide dismutase (From Shi et al., 2007, with permission 100). 
Figure 4. Catalase protein presence and activity in femoral arteries with endothelium from 
control and STZ-treated rats. Western blot demonstrating the presence of catalase (a). Graphic 
representation of the data (b), normalized to β-actin, presented as percentage of control and 
shown as means±SEM; n=6. Catalase activity in femoral arteries with endothelium from 
control and STZ-treated rats (c). Data are normalized to the protein level and are shown as 
means±SEM; n=6. *Significant difference from controls (P<0.05). STZ, streptozotocin (From 
Shi et al., 2007, with permission 100).  
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Figure 5. The presence of COX-1 (a and b) in intact femoral artery from control and 
streptozotocin (STZ)-treated rats, 4 weeks and 12 weeks after the injection of streptozotocin 
(STZ). Data presented are a percentage of control and shown as means±SEM; n=6. 
*Statistically significant difference from control rats (P<0.05) (from Shi et al., 2007 with 
permission 79). 
Figure 6. Effect of antioxidants on concentration-dependent contractions to A23187 in 
femoral arteries with endothelium from STZ-treated rats in the presence of L-NAME. (a) 
Tiron and SOD, n=8–10, (b) deferoxamine, catalase and DETCA; n=12–20. Data are 
expressed as percentage of the reference contraction to 60 mM KCl and are shown as 
means±SEM; *Significant difference (P<0.05) from the controls (rings with endothelium). 
DETCA, diethyldithiocarbamic acid; L-NAME, Nω-nitro-L-arginine methyl ester 
hydrochloride; SOD, superoxide dismutase; STZ, streptozotocin (From Shi et al., 2007, with 
permission 100). 
Figure 7. Proposed mechanisms of endothelial dysfunction in diabetes. Oxidative stress is an 
important contributor to this dysfunction. Oxygen-derive free radicals inactivate NO. 
Increased basal oxidative stress in the endothelium potentiates endothelium-dependent 
contractions. Thus, the balance tips towards vasoconstrictor responses.  
cAMP: cyclic AMP; cGMP: cyclic GMP; COX: Cyclooxygenase; EDHF: Endothelium-
Derived Hyperpolarizing Factor; EP1: Prostanoid Receptor E type I ; NOS: Nitric Oxide 
Synthase; ONOO-: Peroxynitrite; PGH2 : Endoperoxide ; PGI2: Prostacyclin; R: Receptor; 
ROS: Ractive Oxygen Species; TXA2: Thromboxane A2; TP: Thromboxane prostanoid 
receptor 
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